110 results
Page 3 of 6
8-K
EX-99.1
vaks2x193bhkj
1 Mar 22
Bicycle Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
7:00am
8-K
EX-99.1
c4gao
5 Jan 22
Bicycle Therapeutics Announces Continued Clinical Progress and Updates to Management Team
7:14am
8-K
EX-99.1
w2jyvn8
4 Nov 21
Bicycle Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
7:00am
8-K
EX-99.2
il6 gia1si
4 Nov 21
Bicycle Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
7:00am
8-K
EX-99.1
0t0cza7lsujdgz2 ge
26 Oct 21
Bicycle Therapeutics Announces Expansion of Genentech Immuno-Oncology Collaboration
8:58am
424B5
3n7o1 g888
14 Oct 21
Prospectus supplement for primary offering
12:00am
424B5
lui6ztu1l
12 Oct 21
Prospectus supplement for primary offering
6:51am
S-3ASR
s5c6zrs o6
12 Oct 21
Automatic shelf registration
6:04am
8-K
EX-99.2
8yuucc60ra 5fbpm
7 Oct 21
Bicycle Therapeutics Announces Interim BT5528 Phase I Clinical Trial Results and Preliminary Results from Ongoing BT8009 Phase I Clinical Trial
4:14pm
8-K
EX-99.1
o5vrv6l1
7 Oct 21
Bicycle Therapeutics Announces Interim BT5528 Phase I Clinical Trial Results and Preliminary Results from Ongoing BT8009 Phase I Clinical Trial
4:14pm
8-K
EX-99.1
zj6qz
5 Aug 21
Bicycle Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
7:00am
8-K
h1pgpy
13 Jul 21
Bicycle Therapeutics Enters Exclusive License and Collaboration Agreement with Ionis to Develop Targeted Oligonucleotide Therapeutics
7:54am
8-K
EX-99.1
pu64d 9y9
13 Jul 21
Bicycle Therapeutics Enters Exclusive License and Collaboration Agreement with Ionis to Develop Targeted Oligonucleotide Therapeutics
7:54am
DEFA14A
qnh7 703vbnj
16 Jun 21
Additional proxy soliciting materials
12:00am
424B5
c2jz6a4zou
24 May 21
Prospectus supplement for primary offering
4:23pm